Fourth cohort completed in Aptahem’s FIH study

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the completion of an additional cohort in the ongoing double-blinded randomized placebo controlled clinical First in Human (FIH) study.

During the course of the study, there have been signs of interesting effects on clinical markers. Therefore, before starting the next cohort, extended analyses will be performed to gain a greater understanding of Apta-1’s clinical significance. These analyses will form an important basis for the further clinical development of Apta-1.

The objectives with the phase 1a study is to evaluate safety and tolerability of Apta-1 in multiple doses.

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com

Tags: